CD274 and liver cancer: Nowadays, In the era of systematic treatment, the application of TKI drugs and PD-1/PD-L1 has enriched the treatment of liver cancer, expanded the beneficiary group of patients, and median OS has reached 18.1 months or even longer (13, 14, 24, 26).